AU2019206958A1 - PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof - Google Patents
PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof Download PDFInfo
- Publication number
- AU2019206958A1 AU2019206958A1 AU2019206958A AU2019206958A AU2019206958A1 AU 2019206958 A1 AU2019206958 A1 AU 2019206958A1 AU 2019206958 A AU2019206958 A AU 2019206958A AU 2019206958 A AU2019206958 A AU 2019206958A AU 2019206958 A1 AU2019206958 A1 AU 2019206958A1
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- antigen
- binding fragment
- pharmaceutical use
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810023267 | 2018-01-10 | ||
CN201810023267.0 | 2018-01-10 | ||
PCT/CN2019/070982 WO2019137397A1 (fr) | 2018-01-10 | 2019-01-09 | Anticorps pd-l1, fragment de liaison à l'antigène de celui-ci et utilisation pharmaceutique associée |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2019206958A1 true AU2019206958A1 (en) | 2020-07-16 |
Family
ID=67219311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2019206958A Pending AU2019206958A1 (en) | 2018-01-10 | 2019-01-09 | PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
Country Status (12)
Country | Link |
---|---|
US (1) | US11359021B2 (fr) |
EP (1) | EP3741777A4 (fr) |
JP (1) | JP2021510078A (fr) |
KR (1) | KR20200108306A (fr) |
CN (1) | CN111278861B (fr) |
AU (1) | AU2019206958A1 (fr) |
BR (1) | BR112020013475A2 (fr) |
CA (1) | CA3087105A1 (fr) |
MX (1) | MX2020007406A (fr) |
TW (1) | TWI717678B (fr) |
WO (1) | WO2019137397A1 (fr) |
ZA (1) | ZA202004907B (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109608544B (zh) * | 2015-11-17 | 2022-09-16 | 苏州盛迪亚生物医药有限公司 | Pd-l1抗体、其抗原结合片段及其医药用途 |
CN110760517B (zh) * | 2019-10-09 | 2022-04-29 | 天津大学 | 拮抗pd-1骆驼抗体类似物ap基因及蛋白和应用 |
WO2022121846A1 (fr) * | 2020-12-08 | 2022-06-16 | 博际生物医药科技(杭州)有限公司 | Anticorps se liant au pd-l1 et son application |
TWI789679B (zh) * | 2021-01-12 | 2023-01-11 | 大陸商江蘇先聲藥業有限公司 | 抗人程序性死亡配體-1(pd-l1)的抗體及其用途 |
CN115521378B (zh) * | 2021-07-23 | 2023-12-22 | 南京吉盛澳玛生物医药有限公司 | Pd-l1抗体及其用途 |
WO2023046113A1 (fr) * | 2021-09-24 | 2023-03-30 | 广东菲鹏制药股份有限公司 | Anticorps humanisé anti-pd-l1 humain ou fragment de liaison à l'antigène de celui-ci, et son utilisation |
CN115925937A (zh) * | 2022-08-05 | 2023-04-07 | 赛灵药业科技集团股份有限公司北京分公司 | 一种抗体或其片段及其制药用途 |
CN115785269B (zh) * | 2022-11-01 | 2023-09-22 | 四川大学 | 抗pd-l1的抗体及其应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
DK1234031T3 (en) | 1999-11-30 | 2017-07-03 | Mayo Foundation | B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE |
US6803192B1 (en) | 1999-11-30 | 2004-10-12 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
MX2007015942A (es) * | 2005-07-01 | 2008-03-07 | Medarex Inc | Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada. |
CN101104640A (zh) | 2006-07-10 | 2008-01-16 | 苏州大学 | 抗人pd-l1单克隆抗体制备及应用 |
CN102264762B (zh) * | 2008-09-26 | 2018-03-27 | 达纳-法伯癌症研究公司 | 人抗pd‑1、pd‑l1和pd‑l2的抗体及其应用 |
KR101050829B1 (ko) * | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제 |
TWI686405B (zh) * | 2008-12-09 | 2020-03-01 | 建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
EP3192811A1 (fr) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Anticorps pd-1 et pd-l1 et leurs utilisations |
RS60033B1 (sr) * | 2009-11-24 | 2020-04-30 | Medimmune Ltd | Ciljano vezujući agensi usmereni na b7-h1 |
BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
US9212224B2 (en) | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
CN104936982B (zh) | 2012-08-03 | 2020-04-24 | 丹娜法伯癌症研究院 | 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法 |
CA2886433C (fr) | 2012-10-04 | 2022-01-04 | Dana-Farber Cancer Institute, Inc. | Anticorps monoclonaux humains anti pd-l1 et procedes d'utilisation |
AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
EP3633377A1 (fr) | 2013-03-15 | 2020-04-08 | F. Hoffmann-La Roche AG | Biomarqueurs et méthodes de traitement d'états associés à pd-1 et pd-l1 |
WO2014195852A1 (fr) | 2013-06-03 | 2014-12-11 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinaisons d'un anticorps anti-pd-l1 et d'un inhibiteur de mek et/ou d'un inhibiteur de braf |
AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
MA38960A1 (fr) | 2013-09-27 | 2017-10-31 | Genentech Inc | Formulations d'anticorps anti-pdl1 |
MX2017001597A (es) * | 2014-08-05 | 2017-11-17 | Cb Therapeutics Inc | Anticuerpos anti-pd-l1. |
CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
MX2017011644A (es) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
CN106243225B (zh) * | 2015-06-11 | 2021-01-19 | 智翔(上海)医药科技有限公司 | 新型抗-pd-l1抗体 |
CN109608544B (zh) * | 2015-11-17 | 2022-09-16 | 苏州盛迪亚生物医药有限公司 | Pd-l1抗体、其抗原结合片段及其医药用途 |
CN107216389B (zh) * | 2016-03-18 | 2022-03-29 | 和迈生物科技有限公司 | 抗pd-l1纳米抗体及其编码序列和用途 |
KR102343742B1 (ko) | 2016-05-09 | 2021-12-24 | 아이쥐엠 바이오사이언스 인코포레이티드 | 항-pd-l1 항체 |
CN106699891B (zh) * | 2017-01-25 | 2019-04-09 | 北京天广实生物技术股份有限公司 | 一种抗pd-l1抗体、其药物组合物及其用途 |
CN107365383B (zh) * | 2017-07-12 | 2019-04-30 | 苏州大学附属第一医院 | 一种人源化抗人pd-1单克隆抗体及其制备方法、用途与药物 |
WO2019129136A1 (fr) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | Anticorps anti-pd-l1 et ses applications |
-
2019
- 2019-01-09 MX MX2020007406A patent/MX2020007406A/es unknown
- 2019-01-09 AU AU2019206958A patent/AU2019206958A1/en active Pending
- 2019-01-09 WO PCT/CN2019/070982 patent/WO2019137397A1/fr unknown
- 2019-01-09 CA CA3087105A patent/CA3087105A1/fr active Pending
- 2019-01-09 JP JP2020538638A patent/JP2021510078A/ja not_active Ceased
- 2019-01-09 CN CN201980005432.2A patent/CN111278861B/zh active Active
- 2019-01-09 BR BR112020013475-9A patent/BR112020013475A2/pt unknown
- 2019-01-09 US US16/960,297 patent/US11359021B2/en active Active
- 2019-01-09 EP EP19738076.9A patent/EP3741777A4/fr active Pending
- 2019-01-09 KR KR1020207022689A patent/KR20200108306A/ko unknown
- 2019-01-10 TW TW108101001A patent/TWI717678B/zh active
-
2020
- 2020-08-07 ZA ZA2020/04907A patent/ZA202004907B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN111278861B (zh) | 2022-05-27 |
CA3087105A1 (fr) | 2019-07-18 |
RU2020124261A (ru) | 2022-01-25 |
CN111278861A (zh) | 2020-06-12 |
JP2021510078A (ja) | 2021-04-15 |
WO2019137397A1 (fr) | 2019-07-18 |
EP3741777A1 (fr) | 2020-11-25 |
BR112020013475A2 (pt) | 2020-12-08 |
MX2020007406A (es) | 2020-09-14 |
TW201930360A (zh) | 2019-08-01 |
KR20200108306A (ko) | 2020-09-17 |
US20200339692A1 (en) | 2020-10-29 |
EP3741777A4 (fr) | 2021-10-13 |
ZA202004907B (en) | 2022-10-26 |
US11359021B2 (en) | 2022-06-14 |
RU2020124261A3 (fr) | 2022-01-25 |
TWI717678B (zh) | 2021-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019206958A1 (en) | PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
MX2018015393A (es) | Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo. | |
ZA202004701B (en) | Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
SG10201804945WA (en) | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof | |
MX2021011489A (es) | Anticuerpo anti-claudina 18.2 y utilizacion del mismo. | |
MX2021005396A (es) | Anticuerpo anti-cd73, fragmento de union a antigeno y aplicacion del mismo. | |
PH12019502576A1 (en) | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof | |
MX2021009041A (es) | Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. | |
EP3737421A4 (fr) | Procédés de production, purification et formulation de conjugués anticorps-médicaments | |
EP4067387A4 (fr) | Anticorps bispécifique anti-pd-1-anti-vegfa, composition pharmaceutique et leur utilisation | |
MX2020008736A (es) | Formulaciones de anticuerpos b7-h4. | |
MX2018009264A (es) | Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos. | |
WO2020132658A3 (fr) | Tubulysines et conjugués tubulysines-protéines | |
MX2021002531A (es) | Anticuerpo anti-cd38, fragmento de union al antigeno y uso farmaceutico. | |
MX2021010116A (es) | Anticuerpo anti-pd-l1 y uso de este. | |
MX2020010119A (es) | Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo. | |
MX2021004226A (es) | Terapia combinada contra el cáncer. | |
MX2019015914A (es) | Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide. | |
AU2020320233A8 (en) | Anti-HER2/anti-4-1BB bispecific antibody and use thereof | |
MX2023004314A (es) | Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos. | |
MX2018007925A (es) | Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo. | |
MX2020002750A (es) | Anticuerpo il-6r y fragmento de union a antigeno y uso medico. | |
EP4006055A4 (fr) | Anticorps anti-bcma, fragment de liaison à l'antigène de celui-ci et utilisation médicale associée | |
EP3919516A4 (fr) | Anticorps anti-cd79b, fragment de liaison à l'antigène de celui-ci et utilisation pharmaceutique associée | |
MX2018005226A (es) | Formulaciones de anticuerpo anti-factor d. |